熱門資訊> 正文

瑞银将Coherus下调至中性，理由是增长机会有限

2024-08-17 04:32

Coherus生物科學(CHRS) 0

UBS has downgraded Coherus Biosciences (NASDAQ:CHRS) to neutral, citing limited growth opportunities.
"Although CHRS has monetized assets to pay down debt, we believe the cash burn and leverage outlook remain an overhang," UBS said in its note.
It added that it believes a revenue decline of mid-single digit CAGR was “already priced into the stock,” and that it viewed the “setup as balanced risk/reward from these levels."
UBS lowered its price target for the stock to $1.50 from $4.

More on Coherus BioSciences

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects
Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript
Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway
Coherus BioSciences Q2 2024 Earnings Preview
Coherus out licenses Canadian rights to cancer drug Loqtorzi

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。